ALNY - アルナイラム・ファ―マシュ―ティカルズ (Alnylam Pharmaceuticals Inc.) アルナイラム・ファ―マシュ―ティカルズ

 ALNYのチャート


 ALNYの企業情報

symbol ALNY
会社名 Alnylam Pharmaceuticals Inc (アルナイラム・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アルナイラム・ファーマシューティカルズ(Alnylam Pharmaceuticals Inc.)はリボ核酸干渉法(RNAi)に基づく治療薬を開発する生物医薬品会社である。同社の「Alnylam 5x15」は遺伝的疾患の治療向けに、リボ核酸干渉法を用いた新規治療薬の開発及び商品化に注力する。同社の臨床または前臨床開発段階の中核プログラムには、トランスサイレチン媒介性アミロイドーシス(ATTR)の治療向けの「ALN-TTR」、血友病の治療向けの「ALN-APC」、重度の高コレステロール血症の治療向けの「ALN-PCS」、不応性貧血の治療向けの「ALN-HPN」、並びにベータサラセミア及び鎌状赤血球貧血症を含む異常ヘモグロビン症の治療向けの「ALN-TMP」が含まれる。パートナーベースのプログラムとしては、同社は呼吸器合胞体ウイルス(RSV)感染症の治療向けの「ALN-RSV01」、肝癌の治療向けの「ALN-VSP」、並びにハンチントン病(HD)の治療向けの「ALN-HTT」を含む臨床または前臨床開発段階のプログラムを3つ有する。   アルナイラム・ファ―マシュ―ティカルズは米国のバイオテクノロジ―企業。2002年の創業以来、一貫してRNAi(各種疾患の原因となるタンパク質を作り出す遺伝子に直接・選択的に作用する特徴を有する)技術を基盤とした医薬品研究開発を行い、RNAi医薬の研究・開発に必要な多くの特許、技術を保持する。本社はマサチュ―セッツ州ケンブリッジ。   Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
本社所在地 300 Third Street Cambridge MA 02142 USA
代表者氏名 Michael W. Bonney マイケル・W・ボニー
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-551-8200
設立年月日 37742
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 749人
url www.alnylam.com
nasdaq_url https://www.nasdaq.com/symbol/alny
adr_tso
EBITDA EBITDA(百万ドル) -600.14400
終値(lastsale) 83.21
時価総額(marketcap) 8376427179.52
時価総額 時価総額(百万ドル) 8222.408
売上高 売上高(百万ドル) 106.82600
企業価値(EV) 企業価値(EV)(百万ドル) 6804.742
当期純利益 当期純利益(百万ドル) -570.73800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Alnylam Pharmaceuticals Inc. revenues increased 48% to $51.8M. Net loss before extraordinary items increased 35% to $305.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing v increase from $40.5M to $87.2M (expense).

 ALNYのテクニカル分析


 ALNYのニュース

   Alnylam Pharmaceuticals et le Groupe taiba nouent un partenariat pour commercialiser des agents thérapeutiques iARN dans les États du Golfe  2020/07/09 12:39:00 Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), le chef de file des agents thérapeutiques iARN, et taiba Moyen-Orient, un leader spécialisé dans les mal
   Alnylam Pharmaceuticals und Taiba Group kooperieren beim Vertrieb von RNAi-Therapeutika in den Golfstaaten  2020/07/09 09:48:00 Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), das führende Unternehmen für RNAi-Therapeutika, und taiba Middle East, ein führendes Unternehmen für sel
   Alnylam Pharma partners with Taiba Group to commercialize RNAi therapeutics in Gulf states (NASDAQ:ALNY)  2020/07/08 12:42:54 Seeking Alpha
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Taiba Middle East, a rare disease company based in the UAE, have formed a Distribution Agreement for both Onpattr
   Alnylam Pharma Poised to Shoot Higher  2020/07/01 15:48:39 The Street RealMoney
The biopharmaceutical company shows bullish charts that signal a breakout to new all-time highs….ALNY
   COVID-19 Impact and Recovery Analysis - Global Biodefense Market 2020-2024 | Evolving Opportunities with Alexeter Technologies LLC and Alnylam Pharmaceuticals Inc. | Technavio  2020/06/19 03:50:00 Business Wire
LONDON--(BUSINESS WIRE)-- #BiodefenseMarket--The Global Biodefense Market will grow by $ 3.22 billion during 2020-2024
   Alnylam Pharma partners with Taiba Group to commercialize RNAi therapeutics in Gulf states (NASDAQ:ALNY)  2020/07/08 12:42:54 Seeking Alpha
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Taiba Middle East, a rare disease company based in the UAE, have formed a Distribution Agreement for both Onpattr
   Alnylam Pharma Poised to Shoot Higher  2020/07/01 15:48:39 The Street RealMoney
The biopharmaceutical company shows bullish charts that signal a breakout to new all-time highs….ALNY
   COVID-19 Impact and Recovery Analysis - Global Biodefense Market 2020-2024 | Evolving Opportunities with Alexeter Technologies LLC and Alnylam Pharmaceuticals Inc. | Technavio  2020/06/19 03:50:00 Business Wire
LONDON--(BUSINESS WIRE)-- #BiodefenseMarket--The Global Biodefense Market will grow by $ 3.22 billion during 2020-2024
   Here's how 13 top drugmakers are sprinting to develop a coronavirus vaccine or treatment that can halt this pandemic  2020/06/08 16:57:00 Business Insider
Leading drugmakers are researching treatments and vaccines for the novel coronavirus. The small biotech Moderna has leaped to the front of the race, with a vaccine candidate that's already had some results. Pharma giants like Johnson & Johnson, Sanofi, Pfizer, and Merck have also jumped into the vaccine race. There's no assurance the vaccines will work. A vaccine might be available for emergency use by the fall, but likely won't be available widely until 2021 at the earliest, top US health officials have said. In the meantime, treatments are needed for those who have COVID-19, the disease caused by the virus. Drug companies including Gilead Sciences have been looking to repurpose drugs in that effort. Visit Business Insider's homepage for more stories . Drugmakers are racing to find treatments and vaccines to counter the coronavirus pandemic. The companies — including giants like Johnson & Johnson, Sanofi, Merck, and Gilead Sciences — are taking a variety of approaches. Some are hunting for near-term treatment options, either by testing existing drugs or investigating new antivirals or antibodies.
   Alnylam Reports Positive Phase III Results on Lumasarin  2020/06/08 14:00:00 Zacks Investment Research
Alnylam (ALNY) reports positive phase III results from the ILLUMINATE-A study on lumasiran.
   Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved  2019-05-20
Pfizer ( PFE ) was able to obtain FDA approval for its drugs by the name of Vyndaqel and Vyndamax (tafamidis) to treat patients with transthyretin amyloid cardiomyopathy. This is a good approval for the company because it has given itself a great opportunity to target a space with no competi…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アルナイラム・ファ―マシュ―ティカルズ ALNY Alnylam Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)